Avalyn Pharma Inc. (NASDAQ:AVLN) Stock Has Consensus Price Target of $59.20

Avalyn Pharma logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts give Avalyn Pharma a “Moderate Buy” consensus from seven brokerages, with an average 1-year price target of $59.20. Morgan Stanley cut its target from $57 to $53 but maintained an “overweight” rating.
  • Avalyn reported a quarterly loss of $0.67 per share, missing the consensus estimate of a $0.64 loss.
  • Company insiders sold 241,754 shares worth about $7.07 million over the past three months. The stock opened at $28.70, versus a 12-month range of $22.24 to $40.17.
  • Five stocks to consider instead of Avalyn Pharma.

Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) has been given an average rating of "Moderate Buy" by the seven brokerages that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $59.20.

AVLN has been the topic of several analyst reports. Morgan Stanley lowered their target price on Avalyn Pharma from $57.00 to $53.00 and set an "overweight" rating on the stock in a research note on Monday. Wall Street Zen upgraded shares of Avalyn Pharma from a "sell" rating to a "hold" rating in a research report on Saturday, November 14th. Weiss Ratings reissued a "sell (d+)" rating on shares of Avalyn Pharma in a research note on Wednesday, November 11th. Finally, Raymond James Financial initiated coverage on shares of Avalyn Pharma in a research report on Friday, October 2nd. They set an "outperform" rating and a $60.00 price objective for the company.

View Our Latest Stock Analysis on Avalyn Pharma

Insider Activity at Avalyn Pharma

In other Avalyn Pharma news, insider Howard Lazarus sold 13,300 shares of the business's stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $27.90, for a total transaction of $371,070.00. Following the sale, the insider directly owned 13,300 shares in the company, valued at approximately $371,070. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Fmr Llc sold 53,454 shares of the firm's stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $30.21, for a total transaction of $1,614,845.34. Following the completion of the sale, the insider owned 2,056,081 shares of the company's stock, valued at $62,114,207.01. This trade represents a 2.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 241,754 shares of company stock valued at $7,073,165 over the last three months.

Hedge Funds Weigh In On Avalyn Pharma

Several hedge funds have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. purchased a new stake in Avalyn Pharma during the third quarter worth $29,000. Manchester Capital Management LLC purchased a new position in shares of Avalyn Pharma in the third quarter valued at $36,000. Algert Global LLC purchased a new position in shares of Avalyn Pharma in the third quarter valued at $465,000. Profund Advisors LLC acquired a new position in shares of Avalyn Pharma during the 3rd quarter worth $668,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Avalyn Pharma during the 2nd quarter worth $1,321,000.

Avalyn Pharma Trading Up 3.6%

NASDAQ AVLN opened at $28.70 on Friday. The firm's fifty day moving average price is $28.03 and its 200 day moving average price is $29.88. The company has a market capitalization of $1.28 billion and a price-to-earnings ratio of -1.22. Avalyn Pharma has a 12 month low of $22.24 and a 12 month high of $40.17. The company has a debt-to-equity ratio of 0.04, a current ratio of 25.76 and a quick ratio of 25.76.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.03). On average, sell-side analysts expect that Avalyn Pharma will post -3.87 earnings per share for the current fiscal year.

Avalyn Pharma Company Profile

(Get Free Report)

Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company's pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn's inhaled candidates are being studied as potential alternatives to oral treatment.

Featured Stories

Analyst Recommendations for Avalyn Pharma (NASDAQ:AVLN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Avalyn Pharma Right Now?

Before you consider Avalyn Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalyn Pharma wasn't on the list.

While Avalyn Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines